Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics' stock has been influenced by several events over the past six months. Q3 and Q4 2025 earnings were released with EPS of -0.810 USD and -1.380 USD, respectively. The completion of full enrollment in the Phase 3 VANQUISH-2 trial of subcutaneous VK2735 led to a stock surge, and the company plans to advance its oral obesity drug to late-stage trials. M&A speculation has also caused stock surges. Market volatility and geopolitical events have impacted the stock price. Analyst ratings are generally positive, with a consensus of "Moderate Buy" or "Buy" and a median price target of $95.23. There was also insider stock acquisition activity in March 2026.

Information on demand seasonality for Viking Therapeutics' products and services is not readily available. As a clinical-stage biopharmaceutical company, revenue is tied to R&D milestones and potential licensing agreements. There is a mention of seasonality in stock performance, indicating a chance of a "green month" in April.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders, operating in the Biotechnology and Pharmaceutical Products industries. Its pipeline includes VK2809 for NASH and lipid disorders, VK0214 for X-linked adrenoleukodystrophy, and VK2735, a dual GLP-1 and GIP receptor agonist for metabolic disorders like obesity, with both subcutaneous (Phase 3 trials) and oral formulations.

Viking Therapeutics is headquartered in San Diego, California, and operates across the United States through clinical research sites. Its shares are traded on international exchanges, including NASDAQ (US), Deutsche Boerse AG (Germany), London Stock Exchange (UK), and Borsa Italiana (Italy).

Viking Therapeutics' brand reputation has been shaped by its drug pipeline, particularly VK2735, and market speculation. Positive sentiment stems from clinical data and the potential of VK2735, dubbed a potential "Ozempic killer." The company is viewed as an acquisition target, and analysts have a generally strong outlook. However, Jim Cramer advised selling the stock in January 2025, and some analysts have downgraded it due to competition and trial risks.

Viking Therapeutics has a diverse ownership structure. Institutional shareholders hold approximately 62.25% of the stock, with major holders including Vanguard Group Inc. and BlackRock, Inc. Retail investors own about 28.85% of the company, with Ligand Pharmaceuticals Inc. being the largest individual shareholder. Insiders hold approximately 8.90% of the stock.